Use of CFTR modulators in special populations, part 3: Solid organ transplant
Pediatric Pulmonology · 2023
DOI: 10.1002/ppul.26396 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Pulmonology, 2023. Verfasst von Nour K Kadouh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Organ Transplantation, Cystic Fibrosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: None.
Abstract (Originalsprache)
Background
Solid organ transplant (SOT) recipients with cystic fibrosis (CF) may benefit from the pulmonary and extrapulmonary benefits associated with CF transmembrane conductance regulator modulators. Nevertheless, evolution of modulator safety and efficacy data prompts consideration.
Methods
The search terms “transplant” AND “ivacaftor"(IVA) OR "lumacaftor"(LUM) OR "tezacaftor" (TEZ) OR "elexacaftor" (ELX) were utilized to conduct a scoping review of English articles from the period of January 1, 2012 to December 31, 2022. Search results from PubMed and Embase databases were reviewed by title and abstract for relevance. Included studies reported efficacy and safety outcomes of modulators in SOT recipients.
Results
One hundred thirty‐six patients from one cohort study (90 lung transplant recipients) and eight case reports and series (29 lung transplant recipients, 16 liver transplant recipients and one lung/liver transplant patient) were included. Post‐modulator initiation, 33 patients did not necessitate tacrolimus dose adjustments, 10 required dose uptitration, and 43 required dose reductions. Moreover, LUM/IVA use with azole antifungals may lead to subtherapeutic levels but opposing effects sustained tacrolimus levels. Liver transplant recipients were more likely to experience elevations in transaminases requiring pharmacologic or medical interventions. Majority of patients experienced improvements in pulmonary function, fasting blood glucose, hemoglobin, body mass index, and rhinosinusitis symptoms. However, intolerance or lack of benefit prompted discontinuation of ELX/TEZ/IVA in over 40% of lung‐transplant recipients in one study.
Conclusion
Modulator therapy has been reported to produce pulmonary and extra‐pulmonary benefits in the CF population with SOT. Considerations for modulator therapy initiation ought to include modulator pharmacokinetics, concomitant medications, and transplant type due to the complex nature of SOT recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Services, Michigan Medicine, Ann Arbor, Michigan, USA.
- Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
- Sanofi Medical Affairs, Bridgewater, New Jersey, USA.
- Susan B. Meister Child Health Evaluation and Research (CHEAR) Center, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Nour K Kadouh, Joseph Elijah, Hanna Phan
Förderung
- None
Zitieren
APA
Kadouh, N. K., Elijah, J., Fitzgerald, L. J., & Phan, H. (2023). Use of CFTR modulators in special populations, part 3: Solid organ transplant. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26396
Vancouver
Kadouh NK, Elijah J, Fitzgerald LJ, Phan H. Use of CFTR modulators in special populations, part 3: Solid organ transplant. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26396
BibTeX
@article{Kadouh2023,
author = {Kadouh, Nour K and Elijah, Joseph and Fitzgerald, Linda J and Phan, Hanna},
title = {Use of CFTR modulators in special populations, part 3: Solid organ transplant},
journal = {Pediatric Pulmonology},
year = {2023},
doi = {10.1002/ppul.26396}
}
EUVIMED